Anafranil
(Clomipramine)ApprovedSmall molecule
Clomipramine is a tricyclic antidepressant used to treat obsessive-compulsive disorder, a condition where people experience unwanted repetitive thoughts and feel compelled to perform certain behaviors repeatedly. The medication works by increasing serotonin levels in the brain, which helps restore mental balance.[2] Anafranil is currently approved and in use across 3 indications[4].[1]
Anafranil is one of 101 small molecule programs targeting Obsessive-Compulsive Disorder. It is currently in Approved.
3
Indications
9
Total Trials
0
Active Trials
100
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
62 competitors in Treatment Resistant Depression
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Risperdal
WWim Janssens
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Bayer Aspirin
BayerApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Abilify
OtsukaApproved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Mirapex
Boehringer IngelheimApproved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obsessive-Compulsive Disorder4 trials
Premature Ejaculation2 trials
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Dec 29, 1989
ANAFRANIL
NDA NDA019906
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Anafranil drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Clomipramine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]